8-K: Orgenesis Inc. Granted Nasdaq Extension to Regain Compliance with Minimum Bid Price Rule

Orgenesis Inc. has received an extension from Nasdaq until September 23, 2024, to meet the minimum $1.00 per share bid price requirement.

Summary

• Orgenesis Inc. was previously notified by Nasdaq on September 27, 2023, that its stock price had fallen below the required $1.00 per share minimum.
• The company was initially given 180 days, until March 25, 2024, to regain compliance.
• Orgenesis did not meet the minimum bid price requirement during this initial compliance period.
• On March 26, 2024, Nasdaq granted Orgenesis an extension until September 23, 2024, to regain compliance.
• The extension was granted because Orgenesis met all other listing requirements and indicated its intention to perform a reverse stock split if necessary.
• To regain compliance, the company's stock price must close at or above $1.00 for at least 10 consecutive business days before September 23, 2024.
• If compliance is not achieved by September 23, 2024, Orgenesis's stock will be subject to delisting, which the company may appeal.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the risk of delisting and the company's failure to meet the initial compliance deadline. The extension provides some relief, but the underlying issue remains a concern.

Positives

• Nasdaq has granted Orgenesis an extension to regain compliance, avoiding immediate delisting.
• The company has indicated its intention to cure the deficiency, potentially through a reverse stock split.
• Orgenesis meets all other Nasdaq listing requirements except for the minimum bid price.

Negatives

• Orgenesis failed to meet the minimum bid price requirement during the initial compliance period.
• The company's stock is at risk of being delisted if it does not regain compliance by September 23, 2024.
• There is no guarantee that a potential appeal against delisting would be successful.

Risks

• The company's stock price may not reach or remain above $1.00 for the required 10 consecutive business days.
• A reverse stock split may negatively impact the stock price.
• Delisting from Nasdaq could significantly affect the company's ability to raise capital and its stock's liquidity.

Future Outlook

Orgenesis must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before September 23, 2024, to avoid delisting. The company may implement a reverse stock split to achieve this.

Management Comments

• The company has indicated its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.

Industry Context

This situation is not uncommon for companies listed on the Nasdaq Capital Market, which has specific requirements for minimum stock prices. Companies that fail to meet these requirements face the risk of delisting, which can significantly impact their market value and investor confidence.

Comparison to Industry Standards

• Many companies on the Nasdaq Capital Market face similar challenges with maintaining minimum bid prices.
• A reverse stock split is a common strategy used by companies to increase their stock price and regain compliance.
• The Nasdaq listing rules are designed to ensure a certain level of financial stability and investor confidence in listed companies.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty due to the company's financial challenges.
• The company's reputation and ability to attract future investment may be negatively impacted.

Next Steps

• Orgenesis must achieve a closing bid price of at least $1.00 per share for 10 consecutive business days before September 23, 2024.
• The company may implement a reverse stock split to increase its stock price.
• If compliance is not achieved, the company may appeal a delisting determination.

Key Dates

Keywords

Nasdaq, delisting, compliance, minimum bid price, reverse stock split, stock price, Orgenesis